ERK1 / 2 Inhibitor LY3214996 and Abemaciclib for the Treatment of Advanced, Metastatic, or Unresectable Cancer Harboring Mutations in BRAF, RAF1, MEK1 / 2, ERK1 / 2, and NF1
- Have a histological or cytological diagnosis of advanced unresectable or metastatic cancer (American Joint Committee on Cancer Staging Criteria)
- The patient must be, in the judgement of the investigator, an appropriate candidate for experimental therapy, either after available standard therapies (per available local guidelines) have failed to provide clinical benefit for their disease or after the patient has refused standard treatments
- Have one of the following alterations as defined below using a Clinical Laboratory Improvement Act (CLIA)-certified next-generation sequencing test: * Point mutation in BRAF, RAF1, MEK1/2, or ERK1/2 that have been previously characterized to be gain-of-function mutations. These mutations have to be specified as gain-of-function as listed in the OncoKB and/or JAXCKB databases. ** Patients with NSCLC that harbor BRAF V600E treated with prior RAF and/or MEK inhibition therapy will be excluded. ** Patients with tumor types other than NSCLC that harbor BRAF V600E mutations who have been treated and progressed on prior BRAF and/or MEK inhibition will be included. ** Patients with NSCLC that harbor BRAF V600E will only be enrolled if they are not a candidate for FDA approved therapy * Amplification of RAF1 defined as > 6 copies of the respective gene. * Gene fusion in which BRAF, RAF1, MEK1/2, or ERK1/2, is a fusion partner; in which the fusion is determined to be in-frame; and the kinase domain of BRAF, RAF1, MEK1/2, or ERK1/2 is retained * Point mutations, frameshift insertions/deletions, splice site mutations, or stop gain mutations that results in loss-of-function of NF1
- Have measurable disease amenable to biopsy. If biopsy is deemed unsafe at time of procedure, patients will remain eligible for study
- Must be able to provide written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information
- Have a performance status (PS) of 0 or 1 on the Eastern Cooperative Oncology (Group (ECOG) scale (Oken et al. 1982) within 21 (+/-7) days prior to registration for protocol therapy
- Have discontinued previous systemic treatments > 3 weeks for cancer prior to first dose of investigational therapy. Patient must have resolution, except for alopecia, of all clinically significant toxic effects of prior chemotherapy, surgery, or radiotherapy to grade =< 1 by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0
- Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
- Platelets >= 100 x 10^9/L
- Hemoglobin >= 9.0 g/dL * Transfusions to increase the patient’s hemoglobin level to 9 g/dL are not permitted within 1 week prior to the baseline hematology profile
- Total bilirubin =< 1.5 x upper limit of normal (ULN) OR < 2.0 mg/dL in patients with Gilbert’s disease
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN OR =< 5 x ULN if the liver has tumor involvement
- Serum creatinine =< 1.5 x ULN OR calculated creatinine clearance >= 50 mL/min
- Are male patients who are sterile (including vasectomy confirmed by post vasectomy semen analysis), or agree to use an effective method of contraception and not to donate sperm, or who practice total abstinence from heterosexual activity, starting with the first dose of study treatment, during the study, and for at least 6 months following the last dose of study treatment
- Are female patients of non-childbearing potential (surgically sterile after having a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy or postmenopausal), or are female patients of child-bearing potential who are not pregnant, as confirmed by a serum pregnancy test within 14 (+/-7) days prior to receiving first dose of study treatment and who agree to use 2 methods of birth control (hormonal or intrauterine plus a barrier method) or practice total abstinence from heterosexual activity during the study for at least 6 months following the last dose of the study treatment
- Are able to swallow capsules or tablets
- Have an estimated life expectancy of >= 12 weeks, in the judgment of the investigator
- Have a serious concomitant systemic disorder (for example, active infection or a gastrointestinal disorder causing clinically significant symptoms such as nausea, vomiting or diarrhea, or profound immune suppression) that, in the opinion of the investigator, would compromise the patient’s ability to adhere to the protocol
- Have or known activated/reactivated hepatitis A, B, or C (screening is not required)
- Uncontrolled human immunodeficiency virus (HIV) infection are considered ineligible. HIV- infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. Known HIV positive patients who meet the following criteria will be considered eligible: * CD4 count >= 350 cells/mm^3 * Undetectable viral load * Maintained on modern therapeutic regimens utilizing non-CYP interactive agents (i.e. excluding ritonavir) * No history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections
- Have symptomatic and untreated central nervous system (CNS) malignancy or metastasis (screening is not required). * Patients with treated CNS metastases are eligible for this study if they are not currently receiving corticosteroids for their CNS metastasis and/or anticonvulsants. Patient must be > 4 weeks from therapy completion (including radiation and/or surgery) and clinically stable at time of study entry. Brain MRI or head computed tomography (CT) is required at screening for patients with known brain metastases
- Have current hematologic malignancies, acute or chronic leukemia
- Have a second primary malignancy that in the judgment of the principle investigator may affect the interpretation of results
- Have prior malignancies within the last 3 years prior to study enrollment. Patients with carcinoma in situ of any origin and patients with prior malignancies who completed curative intent-treatment and whose likelihood of recurrence is very low, as judged by the principal investigator, will remain eligible for this study. The principal investigator will approve enrollment of patients with prior malignancies in remission before these patients are enrolled
- Are currently enrolled in a clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study
- Have participated, within the last 28 days in a clinical trial involving an investigational product
- Have previously completed or withdrawn from this study or any other study investigating an ERK1/2 inhibitor
- Had prior therapy with an ERK1/2 inhibitor
- Had prior chemotherapy within 3 weeks of study registration
- Had prior non-CNS radiation within 2 weeks of study registration. Please refer to exclusion criteria #4 for patients who have required radiation for CNS disease
- If female, is pregnant, breastfeeding, or planning to become pregnant
- Currently using concomitant medications that are strong inhibitors or inducers of CYP3A4
- Have serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study. * This includes cardiogenic syncope, ventricular arrhythmias, history of sudden cardiac arrest, or severe dyspnea at rest or requiring oxygen therapy. * This includes patients with any evidence of interstitial lung disease (ILD) (not just serious and/or uncontrolled ILD) and any history of severe ILD
I. To evaluate the proportion of patients with objective response to an ERK1/2 inhibitor (LY3214996) in combination with abemaciclib for patients whose tumors harbor pathogenic alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1.
I. To evaluate the safety and tolerability of LY3214996 + abemaciclib as defined by Common Terminology Criteria for Adverse Events (CTCAE) version (v)5 criteria.
II. To evaluate the median progression-free survival (PFS).
II. To evaluate the duration of overall response.
I. To identify potential predictive biomarkers beyond the genomic alteration by which treatment is assigned and/or resistance mechanisms.
II. To evaluate pharmacokinetic parameters of LY3214996 and abemaciclib.
Patients receive ERK1/2 inhibitor LY3214996 orally (PO) once daily (QD) and abemaciclib PO twice daily (BID) and on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 30 days.
Trial Phase Phase II
Trial Type Treatment
Indiana University / Melvin and Bren Simon Cancer Center
- Primary ID CTO-IUSCC-0730
- Secondary IDs NCI-2020-07065
- Clinicaltrials.gov ID NCT04534283